Adaptive humoral immune response and cellular immune status in cancer patients and patients under immunosuppression vaccinated against SARS-CoV-2.

Igor Age KosMaximilian KieferKatharina BrillOnur CetinJoerg Thomas BittenbringManfred AhlgrimmSigrun SmolaStefan LohseKonstantinos ChristofyllakisDominic Kaddu-MulindwaFrank NeumannBewarder MoritzThurner Lorenz

Published in: Expert review of vaccines (2022)

Patients undergoing therapy for cancer or autoimmune diseases are at higher risk of insufficient humoral immune response following COVID-19 vaccination. Furthermore, alterations in the B-cell compartment correlate with lower antibody titers.

Keyphrases

immune response
sars cov
patients undergoing
end stage renal disease
dendritic cells
coronavirus disease
newly diagnosed
ejection fraction
toll like receptor
chronic kidney disease
papillary thyroid
peritoneal dialysis
prognostic factors
young adults
squamous cell
childhood cancer